O Kirk

Summary

Affiliation: Hvidovre University Hospital
Country: Denmark

Publications

  1. ncbi Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort
    O Kirk
    Departments of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    HIV Med 2:43-51. 2001
  2. ncbi [Major breakthroughs in the medical treatment]
    Ole Kirk
    Epidemiklinikken M5132, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 171:787-9. 2009
  3. ncbi Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
    AIDS 15:999-1008. 2001
  4. ncbi Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital
    O Kirk
    Department of Infectious Diseases, Department of Clinical Microbiology, and Clinic of Respiratory Medicine, H S Hvidovre Hospital, University of Copenhagen
    Dan Med Bull 48:84-8. 2001
  5. ncbi Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark
    Blood 98:3406-12. 2001
  6. ncbi Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy
    Ole Kirk
    Coordinating Centre of EuroSIDA, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle, 2650 Hvidovre, Denmark
    Ann Intern Med 137:239-50. 2002
  7. ncbi Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines
    Ole Kirk
    Copenhagen HIV Programme CHIP 044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Curr Opin Infect Dis 17:33-7. 2004
  8. ncbi A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors
    Ole Kirk
    Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark
    Antivir Ther 8:595-602. 2003
  9. ncbi The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study
    S Jensen-Fangel
    Department of Infectious Diseases, Marselisborg Hospital, Aarhus University Hospital, Denmark
    HIV Clin Trials 2:122-7. 2001
  10. ncbi The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
    T L Katzenstein
    Department of Infectious Disease, Rigshospitalet, 2100 O Copenhagen, Denmark
    J Infect Dis 182:744-50. 2000

Detail Information

Publications62

  1. ncbi Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort
    O Kirk
    Departments of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    HIV Med 2:43-51. 2001
    ..To assess predictors for discontinuation and treatment-limiting adverse drug reactions (TLADR) among patients starting their first protease inhibitor (PI)...
  2. ncbi [Major breakthroughs in the medical treatment]
    Ole Kirk
    Epidemiklinikken M5132, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 171:787-9. 2009
    ..The background for the breakthrough and the phases thereof are described and for comparison, the circumstances of major breakthroughs within other medical specialities are mentioned...
  3. ncbi Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
    AIDS 15:999-1008. 2001
    ..To compare the clinical response among patients who initiate protease inhibitor therapies with different virological potency...
  4. ncbi Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital
    O Kirk
    Department of Infectious Diseases, Department of Clinical Microbiology, and Clinic of Respiratory Medicine, H S Hvidovre Hospital, University of Copenhagen
    Dan Med Bull 48:84-8. 2001
    ..We report on the outcome of a study of patients hospitalised with community acquired pneumonia (HCAP) at a Danish university hospital...
  5. ncbi Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark
    Blood 98:3406-12. 2001
    ..After starting HAART, patients with insufficient immunologic and virologic responses were at highest risk of NHL...
  6. ncbi Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy
    Ole Kirk
    Coordinating Centre of EuroSIDA, Department of Infectious Diseases, Hvidovre Hospital, University of Copenhagen, Kettegaard Alle, 2650 Hvidovre, Denmark
    Ann Intern Med 137:239-50. 2002
    ..The safety of interrupting maintenance therapy for previous opportunistic infections other than Pneumocystis carinii pneumonia among patients with HIV infection who respond to potent antiretroviral therapy has not been well documented...
  7. ncbi Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines
    Ole Kirk
    Copenhagen HIV Programme CHIP 044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Curr Opin Infect Dis 17:33-7. 2004
    ..This review explores whether there have been changes in the reporting of randomized trials since the importance of continuous follow-up throughout the study period was initially raised 2 years ago...
  8. ncbi A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors
    Ole Kirk
    Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark
    Antivir Ther 8:595-602. 2003
    ..A triple-class HAART regimen may be associated with a better virological effect than conventional regimens, but may also lead to toxicity and more profound resistance...
  9. ncbi The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study
    S Jensen-Fangel
    Department of Infectious Diseases, Marselisborg Hospital, Aarhus University Hospital, Denmark
    HIV Clin Trials 2:122-7. 2001
    ..To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc)...
  10. ncbi The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
    T L Katzenstein
    Department of Infectious Disease, Rigshospitalet, 2100 O Copenhagen, Denmark
    J Infect Dis 182:744-50. 2000
    ....
  11. ncbi Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study
    B T Røge
    Department of Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    HIV Med 5:344-51. 2004
    ..To investigate the interplay between resistance and adherence in the virological failure of three fundamentally different highly active antiretroviral therapy (HAART) regimens...
  12. ncbi Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD
    O Kirk
    EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark
    Am J Respir Crit Care Med 162:865-72. 2000
    ..These factors could also explain some of the decrease in MAC over time, though there remained a significantly lower risk of MAC than expected...
  13. ncbi Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death
    C Holkmann Olsen
    Copenhagen HIV Programme, Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:96-104. 2007
    ....
  14. ncbi Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance
    D Worm
    Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    HIV Med 3:239-46. 2002
    ..To compare information on body fat changes from questionnaire and clinical examination and to study lipoatrophy in HIV-1 patients on highly active antiretroviral therapy (HAART)...
  15. ncbi The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology
    Justyna D Kowalska
    Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Epidemiology 22:516-23. 2011
    ..The Coding Causes of Death in HIV (CoDe) Project aims to deliver a standardized method for coding the underlying cause of death in HIV-positive persons, suitable for clinical trials and epidemiologic studies...
  16. ncbi Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART
    Daria Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, Denmark
    Scand J Infect Dis 40:908-13. 2008
    ..FI can be used as a clinical marker for disease progression and indirect indicator for initiation/changing cART in settings where laboratory facilities are limited...
  17. ncbi Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression
    Lars Peters
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    J Acquir Immune Defic Syndr 50:457-63. 2009
    ..Conflicting data exist whether hepatitis C virus (HCV) affects the CD4 cell recovery in patients with HIV starting antiretroviral treatment...
  18. ncbi Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
    Jan Gerstoft
    Department of Infectious Diseases at Rigshospitalet, Copenhagen, Denmark
    AIDS 17:2045-52. 2003
    ..CONCLUSION: The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended...
  19. ncbi The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results
    Daria Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Denmark
    Cent Eur J Public Health 16:99-105. 2008
    ..Strategies include creating scientific collaborations for HIV clinicians as well as teaching clinicians about the most advanced HIV management at clinically oriented courses held in eastern Europe...
  20. ncbi A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study
    Justyna D Kowalska
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    HIV Clin Trials 12:109-17. 2011
    ....
  21. ncbi Class of antiretroviral drugs and the risk of myocardial infarction
    Nina Friis Møller
    University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 356:1723-35. 2007
    ..We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction...
  22. ncbi Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina
    Daria N Podlekareva
    University of Copenhagen, Copenhagen HIV Programme, The Panum Institute Building 21 1, Blegdamsvej 3b, 2200 Copenhagen N, Denmark
    AIDS 23:2485-95. 2009
    ..Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina...
  23. ncbi Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir
    J D Kowalska
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    HIV Med 11:200-8. 2010
    ..The number needed to harm (NNH) incorporates information about the underlying risk of MI and the increased RR of MI in patients taking abacavir...
  24. ncbi Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
    Nina Friis-Møller
    Copenhagen HIV Programme CHIP, University of Copenhagen Faculty of Health Science, Copenhagen, Denmark
    Eur J Cardiovasc Prev Rehabil 17:491-501. 2010
    ..Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients...
  25. ncbi The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery
    Christian G Michael
    Department of Infectious Diseases, Hvidovre Hospital, Denmark
    Scand J Infect Dis 34:45-9. 2002
    ..Surprisingly, the naive CD4 + cell count tended to stabilize at a subnormal level after 18 months of HAART. This finding merits further investigation...
  26. ncbi High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome
    Signe W Worm
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    AIDS 24:427-35. 2010
    ....
  27. ncbi Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)
    Signe W Worm
    Copenhagen HIV Programme, University of Copenhagen Faculty of Health Science, Bldg 21 1 Blegdamsvej 3B, DK 2200 Copenhagen, Denmark
    Circulation 119:805-11. 2009
    ..We investigated the impact of DM and preexisting CHD on the development of a new CHD episode among 33,347 HIV-infected individuals in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)...
  28. ncbi Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study
    Signe Westring Worm
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    J Infect Dis 201:318-30. 2010
    ..As with any observational study, our findings must be interpreted with caution (given the potential for confounding) and in the context of the benefits that these drugs provide...
  29. ncbi A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study
    Jens D Lundgren
    EuroSIDA Copenhagen HIV Programme Coordinating Centre, Dept of Infectious Diseases, Hvidovre University Hospital, 2650 Hvidovre, Denmark
    J Infect Dis 185:178-87. 2002
    ..38; 95% confidence interval, 1.33-1.43; P<.0001). The scoring system was validated with remarkably good agreement in the 2 other cohorts. This system can be used in patient and resource management...
  30. ncbi Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study
    Nina Friis-Møller
    DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    AIDS 17:1179-93. 2003
    ..To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies...
  31. ncbi TTV viral load as a marker for immune reconstitution after initiation of HAART in HIV-infected patients
    Chris D Madsen
    Clinical Research Unit, Copenhagen University Hospital, Hvidovre, Denmark
    HIV Clin Trials 3:287-95. 2002
    ..We propose that the change in TTV viral load may be useful in the evaluation of cellular immune response at a functional level in HIV-infected patients who receive HAART...
  32. ncbi K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine
    Birgit T Røge
    Department of Infectious Diseases, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Antivir Ther 8:173-82. 2003
    ..The unexpected high incidence of S68G suggests a functional role of this mutation in viruses harbouring K65R...
  33. ncbi Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial
    Ann Brit Eg Hansen
    Department of Infectious Diseases, Odense University Hospital, Kløvervaenget 2, Odense C, Denmark
    J Clin Epidemiol 61:87-94. 2008
    ..To compare the outcome of highly active antiretroviral therapy (HAART) in HIV-infected patients initiating equivalent regimens within and outside a randomized controlled trial (RCT)...
  34. ncbi Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy
    Ole Kirk
    Copenhagen HIV Programme-044, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark
    Antivir Ther 7:271-81. 2002
    ..Complete follow-up of all patients should be encouraged strongly as this will allow for several complementary analytic approaches and a focus on optimal treatment strategies rather than specific regimens...
  35. ncbi Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors
    O S Søgaard
    Department of Infectious Diseases, Aarhus University Hospital Skejby, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark
    J Infect 66:439-46. 2013
    ..This study aimed to determine incidence rates (IR) and identify risk factors for severe bacterial non-AIDS infections (SBnAI) requiring hospital admission...
  36. ncbi Effects of highly active antiretroviral therapy among HIV-infected patients. Results from randomised and observational studies
    Ole Kirk
    Department of Infectious Diseases, Copenhagen HIV Programme, H:S Hvidovre Hospital, Hvidovre
    Dan Med Bull 51:63-81. 2004
  37. ncbi Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  38. ncbi Response to combination antiretroviral therapy: variation by age
    Ian Weller
    AIDS 22:1463-73. 2008
    ..The poorer virological responses in children may increase the likelihood of emergence of resistance...
  39. ncbi Incidence of abacavir hypersensitivity reactions in euroSIDA
    Wendy P Bannister
    Royal Free and University College Medical School, London, UK
    Antivir Ther 13:687-96. 2008
    ..The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients...
  40. ncbi Changing incidence of central nervous system diseases in the EuroSIDA cohort
    Antonella d'Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, I Sacco Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Ann Neurol 55:320-8. 2004
    ....
  41. ncbi Combination antiretroviral therapy and the risk of myocardial infarction
    Nina Friis-Møller
    N Engl J Med 349:1993-2003. 2003
    ..It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction...
  42. ncbi Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts
    Veronica Miller
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Frankfurt, Germany
    J Infect Dis 186:189-97. 2002
    ..0006; 5.10, P<.0001, respectively, for 4, 3, 2, 1, or no drugs vs. >or=5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment appears to decrease the risk of progression in immunocompromised patients...
  43. ncbi The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    Cancer 100:2644-54. 2004
    ..There continues to be an increased incidence of KS among homosexual men and a greatly reduced incidence of KS among patients with higher CD4 counts...
  44. ncbi Changes in viral load in people with virological failure who remain on the same HAART regimen
    Alessandro Cozzi-Lepri
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    Antivir Ther 8:127-36. 2003
    ..The time-course of selecting more replication-competent virus in patients with virological failure remains to be fully clarified...
  45. ncbi Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited
    Antonia L Moore
    Department of Primary Care and Population Sciences, Royal free and University College School fo Medicine, Hampstead, London, UK
    J Acquir Immune Defic Syndr 32:452-61. 2003
    ..Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis for patients with HIV. There is ongoing debate over a potential gender effect on patient outcome after HAART...
  46. ncbi Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1867-75. 2007
    ..To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART)...
  47. ncbi Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
    Deborah Konopnicki
    Division of Infectious Diseases, Saint Pierre University Hospital, Brussels, Belgium
    AIDS 19:593-601. 2005
    ..Whether hepatitis B (HBV) coinfection affects outcome in HIV-1-infected patients remains unclear...
  48. ncbi Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study
    Cecilia Cabrera
    IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
    Antivir Ther 9:787-800. 2004
    ..Therefore, the interpretation of genotypic resistance for predicting response to regimens containing abacavir remains a major challenge...
  49. ncbi Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy
    Jurgen K Rockstroh
    Department of Medicine I, University Hospital Bonn, Bonn, Germany
    J Infect Dis 192:992-1002. 2005
    ....
  50. ncbi Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 10:779-90. 2005
    ..Little information to address this concern is available from clinical trials as patients with HCV are often excluded...
  51. ncbi Predictors of hypertension and changes of blood pressure in HIV-infected patients
    Rodolphe Thiebaut
    INSERM E0338 epsilont U593, ISPED, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Antivir Ther 10:811-23. 2005
    ..We assessed predictors of changes in systolic (SBP) and diastolic (DBP) blood pressure during follow-up and of the development of hypertension in HIV-infected individuals...
  52. ncbi Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 42:229-37. 2006
    ..Regional variations may identify differences in available antiretroviral drugs or patient management...
  53. ncbi Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study
    Rainer Weber
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH 809a Zurich, Switzerland
    Arch Intern Med 166:1632-41. 2006
    ..An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases...
  54. ncbi Chronic renal failure among HIV-1-infected patients
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, and Department of Primary Care and Population Sciences, Royal Free and University College Medical Schools, Royal Free Campus, Rowland Hill Street, London, UK
    AIDS 21:1119-27. 2007
    ..The role of exposure to antiretrovirals in chronic renal failure (CRF) is not well understood. Glomerular filtration rates (GFR) are estimated using the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) equations...
  55. ncbi Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:2333-7. 2004
    ..Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies...
  56. ncbi Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression
    Andrew N Phillips
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:1795-804. 2004
    ..CONCLUSION: Viral rebound rates in patients who have attained < 50 copies/ml appear to differ according to the specific drugs being used...
  57. ncbi Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
    Enrico Girardi
    Dipartimento di Epidemiologia, Istituto Nazionale per le Malattie Infettive L Spallanzani IRCCS, Via Portuense 292, 00149 Rome, Italy
    Clin Infect Dis 41:1772-82. 2005
    ..We obtained estimates of the incidence of tuberculosis (TB) among patients receiving HAART and identified determinants of the incidence...
  58. ncbi Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 19:2117-25. 2005
    ..Increases in deaths due to liver-related disease (LRD) among HIV-infected individuals have been reported although the influence of combination antiretroviral therapy (cART) on LRD is controversial...
  59. ncbi Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks
    Abdel Babiker
    Int J Epidemiol 31:951-8. 2002
    ..CONCLUSION: These findings suggest that studies reporting a stable trend for particular AIDS diseases over the period 1979-2001 may not have accounted for the competing risks among other events or lack the power to detect smaller trends...
  60. ncbi Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Scand J Infect Dis 38:1092-7. 2006
    ..6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe...
  61. ncbi Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
    Caroline A Sabin
    Lancet 371:1417-26. 2008
    ..The excess risk does not seem to be explained by underlying established cardiovascular risk factors and was not present beyond 6 months after drug cessation...
  62. ncbi [Decline in AIDS and death rates in the EuroSIDA study. An observational study]
    Ole Kirk
    H:S Hvidovre Hospital, Copenhagen HIV Programme
    Ugeskr Laeger 166:2572-6. 2004